Compare NRG Energy Inc (NRG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Novo Nordisk A/S — how do they compare? NRG Energy Inc trades at $107.97 (market cap $22.35B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 7.4× NRG Energy Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 63 Days and Novo Nordisk A/S for 116 Days on average.
| NRG | NVO | |
|---|---|---|
Market Cap | $22.35B | $165.31B |
Volume | 5,011,942 | 11,432,838 |
Sector | Utilities | Health |
52-Week High | $184.03 | $63.98 |
52-Week Low | $95.23 | $35.29 |
Typical Hold Time | 63 Days | 116 Days |
Enterprise Value | $46.30B | $179.56B |
Dividend Yield | 1.79% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $107.97, down 0.59% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $1.49 per share, missing expectations of $1.69, though revenue growth remains positive with 2026 projections at $33.1 billion. Recent developments include a landmark 1.2 GW Texas data center power project and the acquisition of LS Power assets, positioning for growth in hyperscale computing demand.
The investment outlook is cautiously optimistic with strong analyst support (70% buy ratings) and a consensus price target of $202.90 offering significant upside. However, recent earnings misses, rising debt levels (56.42% debt-to-asset ratio in 2025), and execution risks on major capital projects present near-term challenges. The stock's valuation appears reasonable with P/E of 27.69 and P/S of 0.65 relative to sector peers.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
